Vapogenix is a clinical stage company developing a new class of locally acting non-opioid medications to treat pain. Principals of the firm note that , while most pain is localized, available medications are primarily administered orally (systemically) often with resulting side effects. Vapogenix is structured around treating pain at its source. Products of the firm are defined as formulated volatile anesthetics; currently unformulated volatile anesthetics are used only as general anesthetics, by inhalation. The first Vapogenix product - having completed its first clinical trial - is a rapidly acting topical analgesic to alleviate pain associated with venipuncture, venous cannulation and minor dermatological procedures. Products inthe pipeline are being designed to focus on treating wound pain and localized inflammatory pain.
